Reid Rubsamen, MD - (Berkeley, AB Biochemistry & Computer Science; Stanford, MD & MS Computer Science; Harvard Mass General, Anesthesiology Residency; MIT, NIH funded fellowship Computer Science; MS Harvard, Healthcare Management; 71 issued U.S. Patents) - twenty years ago, after developing revolutionary inhalation insulin delivery for diabetes, Reid had the foresight to postulate the certainty of a coming pandemic from a new lethal virus. Hence, two decades ago, the visionary Reid Rubsamen, MD formed Flow Pharma Inc, an R & D company, to begin the research ultimately resulting in a revolutionary targeted killer T-cell immunology platform ten years ago to treat cancer and viruses that he believed would not be defeated by 20^th century antibody platforms.  

Specialties:

-Board Certified Anesthesiologist

-Digital Signal Processing and Mixed Signal Engineer

-Additional expertise in pharmaceutical chemistry, novel dosage form development and regulatory affairs leading to 510(k) and IND filings in the US as well as filings for clinical trials in the UK, Australia and the Netherlands